Ironwood Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in Boston, Massachusetts. The company is dedicated to the discovery, development, manufacturing, and commercialization of pharmaceuticals aimed at treating a range of conditions, including cholesterol, gastrointestinal, and cardiovascular diseases, as well as pain and inflammation.
As of August 16, 2026, Ironwood Pharmaceuticals’ stock was trading at a close price of $4.36 on the Nasdaq exchange. This figure represents a significant fluctuation over the past year, with the stock reaching a 52-week high of $5.78 on January 1, 2026, and a 52-week low of $1.01 on September 3, 2025. These variations reflect the dynamic nature of the biotechnology industry and the market’s response to the company’s performance and strategic initiatives.
The company’s market capitalization stands at approximately $712.18 million, indicating its valuation in the health care sector. With a price-to-earnings (P/E) ratio of 5.49, Ironwood Pharmaceuticals is positioned as a potentially attractive investment, suggesting that the market may anticipate future growth in earnings.
Ironwood Pharmaceuticals continues to focus on its core mission of addressing unmet medical needs through innovative drug development. The company’s efforts are concentrated on enhancing the quality of life for patients by providing effective treatments for complex medical conditions. For more detailed information about Ironwood Pharmaceuticals and its product offerings, stakeholders and interested parties are encouraged to visit the company’s official website at www.ironwoodpharma.com .
In summary, Ironwood Pharmaceuticals, Inc. remains a key entity within the biotechnology industry, leveraging its expertise to develop and commercialize drugs that address critical health issues. The company’s financial metrics and strategic focus underscore its commitment to advancing healthcare solutions and maintaining its competitive edge in the market.
